Revium Rx. Appoints Experienced CFO Amidst Financial Challenges
RVRC has more than doubled off its 52-week low of $0.3 on light trading volume (0.3× avg).
Summary
Revium Rx. announced the resignation of its CFO and the immediate appointment of Igor Bluvstein, an experienced financial leader, as his replacement, signaling a continued management overhaul for the financially distressed company.
Key Events · Executive and Board Changes · RVRC
-
CFO Resignation
Arie Gordashnikov resigned from his position as Chief Financial Officer, effective immediately on May 27, 2026. The company stated his resignation was not due to any disagreement.
-
New CFO Appointment
Igor Bluvstein was appointed as the new Chief Financial Officer, effective immediately on May 27, 2026. Mr. Bluvstein has over 17 years of financial leadership experience, including previous CFO roles at Argent BioPharma Ltd. and G Medical Innovations Holdings Ltd.
-
Compensation Details
In connection with his appointment, Mr. Bluvstein will receive a monthly retainer of NIS17,000 plus VAT.
-
Ongoing Management Restructuring
This CFO change follows the recent appointment of a new CEO and Chairman in April 2026, indicating a broader leadership overhaul for the company, which has recently reported 'going concern' warnings and no product revenue.
Analysis · RVRC · Life Sciences
Revium Rx., a company facing significant financial challenges including a "going concern" warning and no product revenue, has appointed Igor Bluvstein as its new Chief Financial Officer. Mr. Bluvstein brings over 17 years of financial leadership experience from other pharmaceutical and digital health companies, which is a critical move as the company seeks to stabilize its financial position and address its cash burn. This follows recent changes in CEO and Chairman, indicating a broader management restructuring.
At the time of this filing, RVRC was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $101.4M. The 52-week trading range was $0.30 to $50.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.